Smoldering multiple myeloma (SMM) — an early, asymptomatic precursor of multiple myeloma — often exhibits similar genetic alterations as the full-blown disease, suggesting that patients could…
Inserting data from genetically similar patients into a machine-learning algorithm may help predict which multiple myeloma patients will benefit from Velcade (bortezomib) or Revlimid (lenalidomide)…
A triple combination treatment — dendritic cell vaccination plus Revlimid (lenalidomide) and an anti-PD-1 checkpoint inhibitor — led to stronger anti-tumor immune responses against myeloma…